Dopaminergic and adrenergic toxicities on SK-N-MC human neuroblastoma cells are mediated through G protein signaling and oxidative stress

Apoptosis

Volumn 12, Issue 1, 2007, Pages 167-179

  Chan, Anthony S L ^a   Ng, Linda W C ^a   Poon, Lydia S W ^a   Chan, Winnie W Y ^a   Wong, Yung H ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

Apoptosis; Dopamine; G protein; Neurodegeneration; Norepinephrine; Oxidative stress

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; AMINE OXIDASE (FLAVIN CONTAINING); BRIMONIDINE; CATECHOLAMINE; CYCLIC AMP; DOPAMINE; GUANINE NUCLEOTIDE BINDING PROTEIN; ISOPRENALINE; NITRIC OXIDE SYNTHASE; NORADRENALIN; QUINPIROLE; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; BRAIN NERVE CELL; CELL MEDIATED CYTOTOXICITY; CELL STRAIN COS7; CONTROLLED STUDY; DNA DEGRADATION; DRUG CYTOTOXICITY; DRUG SPECIFICITY; FIBROBLAST; HUMAN; HUMAN CELL; KIDNEY CELL; LUNG CARCINOMA; NEUROBLASTOMA CELL; OXIDATIVE STRESS; PRIORITY JOURNAL;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ADRENERGIC BETA-AGONISTS; APOPTOSIS; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; DNA FRAGMENTATION; DOPAMINE; DOPAMINE AGONISTS; GTP-BINDING PROTEINS; HUMANS; ISOPROTERENOL; MODELS, NEUROLOGICAL; NERVE DEGENERATION; NEUROBLASTOMA; NOREPINEPHRINE; OXIDATIVE STRESS; POLY(ADP-RIBOSE) POLYMERASES; SIGNAL TRANSDUCTION;

EID: 33845902811     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-006-0524-8     Document Type: Article

References (51)

1. Burke WJ, Li SW, Chung HD, Ruggiero DA, Kristal BS, Johnson EM, Lampe P, Kumar VB, Franko M, Williams EA, Zahm DS (2004) Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology. 25(1-2):101-115
2. Lang AE, Lozano AM (1998) Parkinson's disease. N Engl J Med.;339 (15):1044-1053
3. Bondareff W, Mountjoy CQ, Roth M (1982) Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology. 32(2):164-168
4. Burke WJ, Galvin NJ, Chung HD, Stoff SA, Gillespie KN, Cataldo AM, Nixon RA (1994) Degenerative changes in epinephrine tonic vasomotor neurons in Alzheimer's disease. Brain Res. 24;661(1-2):35-42
5. Wintermeyer P, Kruger R, Kuhn W, Muller T, Woitalla D, Berg D, Becker G, Leroy E, Polymeropoulos M, Berger K, Przuntek H, Schols L, Epplen JT, Riess O (2000) Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. Neuroreport. 11(10):2079-2082
6. Wersinger C, Sidhu A (2003) Differential cytotoxicity of dopamine and H2O2 in a human neuroblastoma divided cell line transfected with alpha-synuclein and its familial Parkinson's disease-linked mutants. Neurosci Lett. 15;342(1-2):124-128
7. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, Van Der Brug M, Lopez deMunain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 44(4), 595-600
8. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, Gonzalez-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science. 304(5674):1158-1160
9. von Coelln R, Dawson VL, Dawson TM (2004) Parkin-associated Parkinson's disease. Cell Tissue Res. 318(1):175-184
10. Itier JM, Ibanez P, Mena MA et al (2003) Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet. 15;12(18):2277-2291
11. Walkinshaw G, Waters CM (1995) Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. J Clin Invest. 95(6), 2458-2464
12. Chen J, Wersinger C, Sidhu A (2003) Chronic stimulation of D1 dopamine receptors in human SK-N-MC neuroblastoma cells induces nitric-oxide synthase activation and cytotoxicity. J Biol Chem. 278(30):28089-28100
13. Mesulam MM (1996) The systems-level organization of cholinergic innervation in the human cerebral cortex and its alterations in Alzheimer's disease. Prog Brain Res. 109:285-297
14. Hutton M, Hardy J (1997) The presenilins and Alzheimer's disease. Hum Mol Genet. 6(10):1639-1646
15. Zarow C, Lyness SA, Mortimer JA, Chui HC (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60(3):337-341
16. Burke WJ, Li SW, Schmitt CA, Xia P, Chung HD, Gillespie KN (1999) Accumulation of 3,4-dihydroxyphenylglycolaldehyde, the neurotoxic monoamine oxidase A metabolite of norepinephrine, in locus ceruleus cell bodies in Alzheimer's disease: mechanism of neuron death. Brain Res 816(2):633-637
17. Storch A, Ludolph AC, Schwarz J (2004) Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration. J Neural Transm 111:1267-1286
18. Ramsay RR, Singer TP (1986) Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine, by mitochondria. J Biol Chem 261:7585-7587
19. Storch A, Kaftan A, Burkhardt K, Schwarz J (2000) 1-Methyl-6,7-dihydroxy- 1,2,3,4-tetrahydroisoquinoline (salsolinol) is toxic to dopaminergic neuroblastoma SH-SY5Y cells via impairment of cellular energy metabolism. Brain Res 855:67-75
20. Przedborski S, Jackson-Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S, Almer G (2000) The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci 16:135-142
21. Noh JS, Kim EY, Kang JS, Kim HR, Oh YJ, Gwag BJ (1999) Neurotoxic and neuroprotective actions of catecholamines in cortical neurons. Exp Neurol 159(1):217-224
22. Tabakman R, Lecht S, Lazarovici P (2004) Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease? Bioessays 26(1):80-90
23. Burke WJ, Kristal BS, Yu BP, Li SW, Lin TS (1998) Norepinephrine transmitter metabolite generates free radicals and activates mitochondrial permeability transition: a mechanism for DOPEGAL-induced apoptosis. Brain Res 787:328-332
24. Li SW, Lin T-S, Minteer, Burke WJ (2001) 3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis. Mol Brain Res 93:1-7
25. Kristal BS, Conway AD, Brown AM, Jain JC, Ulluci PA, Li SW et al (2001) Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. Free Radic Biol Med 30:924-931
26. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD (1997) The release of cytochrome c from mitochondria: a primary site for Bcl2 regulation of apoptosis. Science 275:1132-1136
27. Wallace DC (1999) Mitochondrial diseases in man and mouse. Science 283:1482-1488
28. Kothakota S, Azuma T, Reinhard C, Klippel A, Tang J, Chu K, McGarry TJ, Kirschner MW, Koths K, Kwiatkowski DJ, Williams LT (1997) Caspase-3-generated fragment of gelsolin: effector of morphological changes in apoptosis. Science 278:294-298
29. Scarlett SL, Murphy MP (1997) Release of apoptogenic proteins from mitochondrial intermembrane space during mitochondrial permeability transition. FEBS Lett 418:282-286
30. Yip EC, Chan AS, Pang H, Tam YK, Wong YH. Protocatechuic acid induces cell death in HepG2 hepatocarcinoma cells through a c-Jun N-terminal kinase-dependent mechanism. Cell Biol Toxical 22(4):293-302
31. Zhen X, Uryu K, Wang HY, Friedman E (1998) D1 Dopamine receptor agonists mediate activation of p38 mitogen-activated protein kinase and c-Jun amino-terminal kinase by a protein kinase A-dependent mechanism in SK-N-MC human neuroblastoma cells. J Pharmacol Exp Ther 54:453-458
32. Chan AS, Yeung WW, Wong YH (2005) Integration of G Protein Signals by Extracellular Signal-regulated Protein Kinases in SK-N-MC Neuroepithelioma Cells. J Neurochem 94:1457-1470
33. Jin Z, El-Deiry WS (2005) Overview of cell death signaling pathways. Cancer Biol Ther 4(2):139-163
34. Chauhan V, Chauhan A (2006) Oxidative stress in Alzheimer's disease. Pathophysiology. 13(3):195-208
35. Halliwell B (2006) Oxidative stress and neurodegeneration: where are we now? J Neurochem 97(6):634-1658
36. Luo Y, Umegaki H, Wang X, Abe R, Roth GS (1998) Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway. J Biol Chem 273(6):3756-3764
37. Andersen JK (2004) Oxidative stress in neurodegeneration: cause or consequence? Nat Med 10 Suppl:S18-S25
38. Lahiri DK, Farlow MR, Sambamurti K, Greig NH, Giacobini E, Schneider LS (2003) A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr Drug Targets 4(2):97-112
39. Riederer P, Danielczyk W, Grunblatt E (2004) Monoamine oxidase-B inhibition in Alzheimer's disease. Neurotoxicology 25(1-2):271-277
40. Burke WJ, Li SW, Schmitt CA, Zahm DS, Chung HD, Conway AD et al (2000) Catecholamine-derived aldehyde neurotoxins. In: Storch A, Collins MA (eds). Neurotoxic factors in Parkinson's disease and related disorders. New York (NY), Kluwer Academic Publishers, pp 167-180
41. Zhou XM, Fishman PH (1991) Desensitization of the human b1-adrenergic receptor. Involvement of the cyclic AMP-dependent but not a receptor-specific protein kinase. J Biol Chem 266(12):7462-7468
42. Sidhu A (1997) Regulation and expression of D-1, but not D-5, dopamine receptors in human SK-N-MC neuroblastoma cells. J Recept Signal Transduct Res 17(5):777-784
43. Sidhu A, Kimura K, Uh M, White BH, Patel S (1998) Multiple coupling of human D5 dopamine receptors to guanine nucleotide binding proteins Gs and Gz. J Neurochem. 70(6):2459-2467
44. Ryman-Rasmussen JP, Nichols DE, Mailman RB (2005) Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists. Mol Pharmacol. 68(4):1039-1048
45. Pifl C, Hornykiewicz O, Giros B, Caron MG (1996) Catecholamine transporters and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: studies comparing the cloned human noradrenaline and human dopamine transporter. J Pharmacol Exp Ther 277(3):1437-1443
46. Saelens X, Festjens N, Vande Walle L, van Gurp M, van Loo G, Vandenabeele P (2004) Toxic proteins released from mitochondria in cell death. Oncogene 23(16):2861-2874
47. Chen J, Rusnak M, Luedtke RR, Sidhu A (2004) D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade. J Biol Chem 279:39317-39330
48. Sharpe JC, Arnoult D, Youle RJ (2004) Control of mitochondrial permeability by Bcl-2 family members. Biochim Biophys Acta 1644(2-3):107-113
49. Jassen AK, Yang H, Miller GM, Calder E, Madras BK (2006) Receptor regulation of gene expression of axon guidance molecules: implications for adaptation. Mol Pharmacol 70(1):71-77
50. Shirvan A, Ziv I, Fleminger G, Shina R, He Z, Brudo I, Melamed E, Barzilai A (1999) Semaphorins asmediators of neuronal apoptosis. J Neurochem 73(3):961-971
51. Wick MM (1978) Dopamine: a novel antitumor agent active against B-16 melanoma in vivo. J Invest Dermatol 71(2):163-164